Skip to main content
ARCT
NASDAQ Life Sciences

Meiji Buys $50M of Arcturus Stock at 80% Premium, Expands mRNA Collaboration

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$8.52
Mkt Cap
$240.956M
52W Low
$5.5
52W High
$17.96
52W Position info
55% above low
Off High info
53% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

ARCT sits 55% above its 52-week low of $5.5 on light trading volume (0.4× avg).

Summary

Arcturus sold 2,466,395 shares to Meiji Seika Pharma for $50 million at $20.27 each, an 80% premium to the 30-day average, alongside an ARCT-154 license and a pandemic-preparedness MOU. The stake equals 7.9% of post-deal shares, and ~$11.1 million of the premium is refundable if no definitive license deal is signed by May 31, 2027.


Key Events · M&A and Partnerships · ARCT

  • Meiji Invests $50M at 80% Premium

    Meiji Seika Pharma bought 2,466,395 newly issued shares for $50.0 million, or $20.27 per share — an 80% premium to the average closing price over the 30 trading days through November 11, 2026.

  • Stake Equals 7.9% of Post-Deal Shares

    The placement represents 7.9% of Arcturus' outstanding shares after the transaction and closed concurrently with signing; proceeds fund ARCT-2601 in OTC deficiency and clinical validation of LUNAR 2.0.

  • $11.1M of Premium Is Refundable

    Should the parties fail to sign a definitive license agreement contemplated by the MOU by May 31, 2027, Arcturus must refund 50% of the premium, about $11.1 million, in cash or at its election shares.

  • License Signed, Pandemic Deal Only an MOU

    A binding exclusive license covers ARCT-154 technology for an undisclosed therapeutic area, with Meiji paying development and commercialization costs; the Japan pandemic-preparedness license remains a non-binding MOU with no obligation to sign.


Analysis · ARCT · Life Sciences

A strategic pharma partner is paying $20.27 a share — 80% above the 30-day average closing price through November 11 — for 2,466,395 newly issued shares, roughly 7.9% of the post-deal share count. The structure is unusual: dilution of about 8% is real, but it comes with $50 million of cash and an explicit third-party endorsement of the LUNAR platform at a price well above where the stock has traded. Proceeds are earmarked for ARCT-2601 in OTC deficiency and to clinically validate LUNAR 2.0, extending the runway disclosed in the Q3 10-Q ($184.8M cash) rather than plugging a hole. The catch: $11.1 million of the premium is refundable in cash or stock if a definitive license agreement is not signed by May 31, 2027, and the pandemic-preparedness piece is only a non-binding MOU — so part of the headline value is contingent.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARCT was trading at $8.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $241M. The 52-week trading range was $5.50 to $17.96. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARCT - Latest Insights

ARCT
Nov 05, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.90
Real-time Price: $9.44 info
Change: -$0.460 (-5%) info
Market Cap: $240.956M info
ARCT
Nov 05, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.34
Real-time Price: $9.44 info
Change: +$0.100 (+1%) info
Market Cap: $240.956M info
ARCT
Sep 28, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $13.80
Real-time Price: $9.44 info
Change: -$4.36 (-32%) info
Market Cap: $240.956M info
ARCT
Sep 23, 2026, 4:29 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $13.90
Real-time Price: $9.44 info
Change: -$4.46 (-32%) info
Market Cap: $240.956M info
ARCT
Sep 23, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.90
Real-time Price: $9.44 info
Change: -$4.46 (-32%) info
Market Cap: $240.956M info